Plasmatic Plasminogen Activator Inhibitor Activity in Patients with Primary Breast Cancer

• References

• 1 Niwano H, Takahashi H, Taewaki W, Wada K, Seki Y, Shibata A. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Blood Coagulation and Fibrinolysis 1992; 3: 0389-0393
• 2 Pappot H, Gardsvoll H, Perdersen AN, Grondahl-Hansen J, Pyke C, Brunner N. Plasminogen Activator Inhibitor 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe Seyler 1995; 376: 0259-0269
• 3 de JongE, Knot EAR, Iburg AHC, Rijken DC, Veenhof KHN, Dooijewaard G, ten CasteJW. Increased plasminogen activator inhibition levels in malignancy. Thromb Haemost 1987; 57: 0140-0143
• 4 Newland JR, Haire WD. Elevated Plasminogen Activator Inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991; 96: 0602-0604
• 5 Rocha E, Páramo JA, Fernández FJ, Cuesta B, Hernández M, Paloma MJ, Rifón J. Clotting activation and impairement of fibrinolysis in malignancy. Thrombosis Research 1989; 54: 0699-0707
• 6 von Tempelhoff G-F. Changes of hemorheology and clotting in different gynecologic malignancies. Clin Hemorheology 1995; 54: 0261-0262
• 7 Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer and Metastasis Reviews 1992; 11: 0291-0311
• 8 Casslén B, Bossmar T, Lecander I, Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 1994; 30 A: 1302-1309